scholarly journals Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults

2009 ◽  
Vol 20 (2) ◽  
pp. e24-e34 ◽  
Author(s):  
Marianne Harris ◽  
Jonathan B Angel ◽  
Jean-Guy Baril ◽  
Anita Rachlis ◽  
Benoit Trottier
Keyword(s):  
Antiretroviral Treatment ◽  
Disease Status ◽  
Hiv Treatment ◽  
Hiv Disease ◽  
Consensus Guidelines ◽  
Expert Opinions ◽  
Hiv Management ◽  
Predictors Of Response ◽  
Conference Presentations ◽  
Group Members

BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV management was convened. Their goal was to develop guidance specifically for Canadian HIV-treating physicians on the appropriate use of etravirine (TMC125, Intelence, Tibotec BVBA, Belgium) in adult HIV-infected patients.METHODS: Evidence from the published literature, conference presentations and expert opinions of the group members were used to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, and from seven other physicians across Canada with clinical HIV treatment expertise and experience in the use of etravirine, as well as two Canadian scientists with HIV expertise. The final recommendations represent the core group’s consensus agreement, taking all feedback into consideration.RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in the optimal use of etravirine. The issues considered included HIV disease status, antiretroviral treatment history, drug resistance profiles, predictors of response to etravirine, background antiretroviral regimen and drug-drug interactions.

scholarly journals Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines

2009 ◽  
Vol 20 (3) ◽  
pp. e67-e80 ◽  
Author(s):  
Anita Rachlis ◽  
Jonathan B Angel ◽  
Marianne Harris ◽  
Stephen D Shafran ◽  
Rachel Therrien ◽  
...  
Keyword(s):  
Hiv Treatment ◽  
Consensus Guidelines ◽  
Antiretroviral Drug Resistance ◽  
Expert Opinions ◽  
Viral Load Reduction ◽  
Hiv Management ◽  
Antiretroviral Drug ◽  
Conference Presentations ◽  
Group Members ◽  
Canadian Group

BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress®, Merck Frosst Canada Inc) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir’s role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.

scholarly journals Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

2010 ◽  
Vol 21 (4) ◽  
pp. 159-172 ◽  
Author(s):  
Anita Rachlis ◽  
Marianne Harris ◽  
Richard Lalonde ◽  
Stephen D Shafran ◽  
Cécile Tremblay ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Hiv Treatment ◽  
Care Providers ◽  
Expert Opinions ◽  
Hiv Management ◽  
Conference Presentations ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Group Members

BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who treat HIV infection) on the appropriate use of maraviroc (UK-427,857) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as the expert opinions of the group members were considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from four other physicians across Canada with expertise in HIV treatment and experience with the use of maraviroc. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians and other health care providers in the optimal use of maraviroc. The recommendations were considered in light of the fact that the decision to include maraviroc in an antiretroviral regimen depends not only on issues that concern all antiretroviral agents, such as efficacy, safety, resistance and drug interactions, but also on the issue of viral tropism, which is unique to maraviroc and other CCR5 inhibitors.

scholarly journals Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients

2006 ◽  
Vol 17 (3) ◽  
pp. 155-163 ◽  
Author(s):  
Anita Rachlis ◽  
Jonathan Angel ◽  
Marianne Harris ◽  
Richard Lalonde ◽  
Fiona Smaill ◽  
...  
Keyword(s):  
Antiretroviral Drugs ◽  
Aids Patients ◽  
Expert Opinions ◽  
Background Regimen ◽  
Hiv Management ◽  
Predictors Of Response ◽  
Group Members ◽  
Selection For ◽  
Subsequent Patient ◽  
Hiv Aids

BACKGROUND AND OBJECTIVES:An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDS patients with resistance to other antiretroviral drugs.METHODS:Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement.RESULTS AND CONCLUSIONS:The recommendations were developed to guide physicians in optimal practices in patient selection for enfuvirtide treatment and subsequent patient management. The issues considered include positive predictors of response to enfuvirtide, stage of disease, optimization of the background regimen, early indicators of enfuvirtide response, and patient education and support.

Beliefs in Antiretroviral Treatment and Self-Efficacy in HIV Management are Associated with Distinctive HIV Treatment Trajectories

2016 ◽  
Vol 22 (3) ◽  
pp. 887-895 ◽  
Author(s):  
Limin Mao ◽  
John de Wit ◽  
Philippe Adam ◽  
Jeffrey J. Post ◽  
Sean Slavin ◽  
...  
Keyword(s):  
Self Efficacy ◽  
Antiretroviral Treatment ◽  
Hiv Treatment ◽  
Hiv Management

scholarly journals Association of poor sleep with depressive and anxiety symptoms by HIV disease status

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Elizabeth Daubert ◽  
Audrey L French ◽  
Helen J. Burgess ◽  
Anjali Sharma ◽  
Deborah Gustafson ◽  
...  
Keyword(s):  
Disease Status ◽  
Anxiety Symptoms ◽  
Poor Sleep ◽  
Hiv Disease

Oral Manifestations of Pediatric Human Immunodeficiency Virus Infection: A Review of the Literature

PEDIATRICS ◽  
1996 ◽  
Vol 97 (3) ◽  
pp. 380-388
Author(s):  
Mark W. Kline
Keyword(s):  
Disease Status ◽  
Oral Lesions ◽  
Oral Manifestations ◽  
Hiv Disease ◽  
Continuous Assessment ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Adults And Children ◽  
Available Information ◽  
Distinguishing Features

Oral lesions are the source of substantial HIV-associated morbidity in both adults and children. In addition, certain oral lesions are markers for progressive immunologic dysfunction and HIV disease progression. For these reasons, careful and continuous assessment of oral health is an integral part of comprehensive HIV disease treatment. Available information suggests that HIV-infected children have many of the same oral manifestations observed in HIV-infected adults, but distinguishing features have been noted. Prospective pediatric studies are needed to determine the prevalence and natural history of oral lesions, to examine the relationships between immunologic and virologic markers of HIV disease status and the occurrence of oral manifestations, to evaluate changes in the oral microbial flora of HIV-infected children over time, and to assess the causative nature of oral lesions comprehensively.

scholarly journals Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naïve adults in Botswana

2016 ◽  
Vol 115 (12) ◽  
pp. 2114-2121 ◽  
Author(s):  
S. S. Martinez ◽  
A. Campa ◽  
H. Bussmann ◽  
S. Moyo ◽  
J. Makhema ◽  
...  
Keyword(s):  
Cell Count ◽  
Disease Progression ◽  
Fat Mass ◽  
Antiretroviral Treatment ◽  
Obesity Paradox ◽  
Hiv Disease ◽  
Time To Event ◽  
Cd4 Cell Count ◽  
Cd4 Cell

AbstractAn obesity paradox has been proposed in many conditions including HIV. Studies conducted to investigate obesity and its effect on HIV disease progression have been inconclusive and are lacking for African settings. This study investigated the relationship between overweight/obesity (BMI≥25 kg/m2) and HIV disease progression in HIV+ asymptomatic adults not on antiretroviral treatment (ART) in Botswana over 18 months. A cohort study in asymptomatic, ART-naïve, HIV+ adults included 217 participants, 139 with BMI of 18·0–24·9 kg/m2 and seventy-eight participants with BMI≥25 kg/m2. The primary outcome was time to event (≥25 % decrease in cluster of differentiation 4 (CD4) cell count) during 18 months of follow-up; secondary outcomes were time to event of CD4 cell count<250 cells/µl and AIDS-defining conditions. Proportional survival hazard models were used to compare hazard ratios (HR) on time to events of HIV disease progression over 18 months. Higher baseline BMI was associated with significantly lower risk of an AIDS-defining condition during the follow-up (HR 0·218; 95 % CI 0·068, 0·701; P=0·011). Higher fat mass at baseline was also significantly associated with decreased risk of AIDS-defining conditions during the follow-up (HR 0·855; 95 % CI 0·741, 0·987; P=0·033) and the combined outcome of having CD4 cell count≤250/µl and AIDS-defining conditions, whichever occurred earlier (HR 0·918; 95 % CI 0·847, 0·994; P=0·036). All models were adjusted for covariates. Higher BMI and fat mass among the HIV-infected, ART-naïve participants were associated with slower disease progression. Mechanistic research is needed to evaluate the association between BMI, fat mass and HIV disease progression.

Sign in / Sign up

Export Citation Format

Share Document